Literature DB >> 22151756

Overexpression of Id3 induces apoptosis of A549 human lung adenocarcinoma cells.

X-J Li1, C-D Zhu, W Yu, P Wang, F-F Chen, X-Y Xia, B Luo.   

Abstract

OBJECTIVES: Inhibitor of differentiation 3 (Id3) protein has been implicated in the control of multiple cell death signalling pathways and in aetiology of numerous diseases. The aims of this study were to construct a recombinant eukaryotic expression vector (pEGFP/Id3), containing human Id3 (hId3) fused with enhanced green fluorescent protein (EGFP), and to determine effects of ectopic Id3 overexpression, on human lung adenocarcinoma cell (A549) proliferation.
MATERIALS AND METHODS: Human Id3 cDNA was inserted into pEGFP-N1 vector to yield the recombinant eukaryotic expression vector pEGFP/Id3. Cells were transfected with pEGFP or pEGFP/Id3, and proliferation of EGFP-expressing cells was monitored by flow cytometry (FCM) and confocal fluorescence microscopy. RT-PCR, immunoblotting and immunocytochemistry were used to assess Id3 mRNA transcription and protein expression. Apoptosis was evaluated by Annexin V/7-AAD staining and FCM, while nuclear morphology of apoptotic cells was examined using Hoechst 33258 staining.
RESULTS: Over 4 days transfection with pEGFP, the proportion of EGFP-positive A549 cells peaked at approximately 60% by 48 h and remained stable over the next 48 h. In contrast, the proportion of EGFP-positive cells in cultures transfected with pEGFP/Id3 decreased from a peak of 60% at 48 h to <5% at 96 h, suggesting that Id3 expression inhibited cell proliferation or survival. Annexin V/7-AAD and Hoechst 33258 staining revealed significantly higher rates of apoptosis in pEGFP/Id3-transfected cells.
CONCLUSION: Overexpression of Id3 triggered apoptosis in A549 human lung adenocarcinoma cells, implicating Id3 in negative control of tumour growth. These Id3-induced pro-apoptotic signalling pathways require further study, but this preliminary investigation suggests that Id3 regulation could be exploited in anti-tumour therapies.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22151756      PMCID: PMC6495221          DOI: 10.1111/j.1365-2184.2011.00792.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  23 in total

1.  Targeting Id1 and Id3 inhibits peritoneal metastasis of gastric cancer.

Authors:  Takeshi Tsuchiya; Yurai Okaji; Nelson H Tsuno; Daisuke Sakurai; Naoyuki Tsuchiya; Kazushige Kawai; Kentaro Yazawa; Masahiro Asakage; Jun Yamada; Satomi Yoneyama; Joji Kitayama; Takuya Osada; Toshiaki Watanabe; Katsushi Tokunaga; Koki Takahashi; Hirokazu Nagawa
Journal:  Cancer Sci       Date:  2005-11       Impact factor: 6.716

2.  Id3 induces a caspase-3- and -9-dependent apoptosis and mediates UVB sensitization of HPV16 E6/7 immortalized human keratinocytes.

Authors:  C M Simbulan-Rosenthal; A Daher; V Trabosh; W-C Chen; D Gerstel; E Soeda; D S Rosenthal
Journal:  Oncogene       Date:  2006-01-30       Impact factor: 9.867

Review 3.  The multiple roles of Id-1 in cancer progression.

Authors:  Ming-Tat Ling; Xianghong Wang; Xiaomeng Zhang; Yong-Chuan Wong
Journal:  Differentiation       Date:  2006-12       Impact factor: 3.880

Review 4.  Molecular mechanisms regulating expression and function of transcription regulator inhibitor of differentiation 3.

Authors:  Robert Wai-Sui Lim; Jin-Mei Wu
Journal:  Acta Pharmacol Sin       Date:  2005-12       Impact factor: 6.150

5.  Expression of Id proteins in human hepatocellular carcinoma: relevance to tumor dedifferentiation.

Authors:  Bazarragchaa Damdinsuren; Hiroaki Nagano; Motoi Kondo; Hirofumi Yamamoto; Nobuaki Hiraoka; Tameyoshi Yamamoto; Shigeru Marubashi; Atsushi Miyamoto; Koji Umeshita; Keizo Dono; Shoji Nakamori; Ken-Ichi Wakasa; Masato Sakon; Morito Monden
Journal:  Int J Oncol       Date:  2005-02       Impact factor: 5.650

Review 6.  ID proteins as targets in cancer and tools in neurobiology.

Authors:  Antonio Iavarone; Anna Lasorella
Journal:  Trends Mol Med       Date:  2006-10-30       Impact factor: 11.951

7.  Interaction of Inhibitor of DNA binding 3 (Id3) with Gut-enriched Krüppel-like factor (GKLF) and p53 regulates proliferation of vascular smooth muscle cells.

Authors:  Kerstin Wassmann; Cornelius F H Mueller; Ulrich M Becher; Christian Werner; Alexander Jung; Sebastian Zimmer; Martin Steinmetz; Georg Nickenig; Sven Wassmann
Journal:  Mol Cell Biochem       Date:  2009-07-19       Impact factor: 3.396

8.  Ebf1-mediated down-regulation of Id2 and Id3 is essential for specification of the B cell lineage.

Authors:  Melissa A Thal; Thiago L Carvalho; Ti He; Hyung-Gyoon Kim; Hua Gao; James Hagman; Christopher A Klug
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-02       Impact factor: 11.205

9.  ID genes mediate tumor reinitiation during breast cancer lung metastasis.

Authors:  Gaorav P Gupta; Jonathan Perk; Swarnali Acharyya; Paola de Candia; Vivek Mittal; Katia Todorova-Manova; William L Gerald; Edi Brogi; Robert Benezra; Joan Massagué
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-28       Impact factor: 11.205

10.  Increased Id-1 expression is significantly associated with poor survival of patients with prostate cancer.

Authors:  Shiva S Forootan; Yong-Chuan Wong; Andrew Dodson; Xianghong Wang; Ke Lin; Paul H Smith; Christopher S Foster; Youqiang Ke
Journal:  Hum Pathol       Date:  2007-06-28       Impact factor: 3.466

View more
  2 in total

1.  Effects of upregulation of Id3 in human lung adenocarcinoma cells on proliferation, apoptosis, mobility and tumorigenicity.

Authors:  F-F Chen; Y Liu; F Wang; X-J Pang; C-D Zhu; M Xu; W Yu; X-J Li
Journal:  Cancer Gene Ther       Date:  2015-09-18       Impact factor: 5.987

2.  Inhibitor of DNA binding 3 reverses cisplatin resistance in human lung adenocarcinoma cells by regulating the PI3K/Akt pathway.

Authors:  Fang-Fang Chen; Xing Lv; Qin-Fei Zhao; Yu-Zhong Xu; Shu-Sheng Song; Wei Yu; Xiao-Jun Li
Journal:  Oncol Lett       Date:  2018-05-31       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.